Acute Migraine Drugs Market

Acute Migraine Drugs Market Size by Route of Administration (Injection, Oral, & Others), Treatment (Pain Relieving & Preventive), End-User, Regions, Global Industry Analysis, Share, Growth, Trends, and Forecast 2022 to 2030

Base Year: 2021 Historical Data: 2019-20
  • Report ID: TBI-12885
  • Published Date: Aug, 2022
  • Pages: 238
  • Category: Healthcare
  • Format: PDF
Buy @ $4700.00 Request Sample PDF

The global acute migraine drugs market is expected to reach USD 9.26 billion by 2030, at a CAGR of 8.90% from 2022 to 2030. Acute migraine drug market growth would be driven by the increasing need for migraine therapy, growing demand from pharmaceutical enterprises, hospitals, and medical research laboratories, and the rising number of manufacturers.

Market Overview:

The global acute migraine drugs market is anticipated to grow due to the increasing majority of neurological disorders, growing workload, increased alcohol consumption, lifestyle changes, and increasing demand for quality drugs. Similarly, the increased patient awareness about migraine control therapy and the understanding of migraine and its treatment leads to market development. Rising research & development investment, resulting in an extensive pipeline of medicines, are essential drivers anticipated to boost the market's development. Regardless, a lack of proper undiagnosed and diagnosed cases, drug side effects, strict government regulations, and a growing tendency for alternative treatments are significant limitations to the market's development. Signs like numbness, nausea, vomiting, and trouble speaking may be present. An alert sensation called an aura develops before or with some individuals' headaches. Optical disturbances, like a flashlight or blind patches, or other troubles, such as tingling on one side of the face, arm, or leg, and difficulty communicating, may all be an atmosphere. Migraine is a neurological disorder that induces headaches, sickness, incapacity to smell, expanded sensitivity to sound and light, and numbness, among additional symptoms.

Get an overview of this study by requesting a free sample

Market Dynamics:

Drivers:
  • The increased demand for high-quality medicines

The increased need for high-quality drugs and rising awareness among individuals about the prevention & treatment of migraine is expected to support the sales of acute migraine treatment options. The growing consumption of alcoholic drinks, rising smoking patterns, and the advancement in work pressure are other factors expected to predict well for the global market.

Restraints:
  • Side-effects of drugs specified for migraine

Headache, sleepiness, nausea, dry mouth, dizziness, fatigue, hot or cold sensations, chest pain, flushing, sense of tightness around the chest or throat, numbness. These medications cause the narrowing of the blood vessels. People shouldn't take these medications if they have a history of coronary artery disease, myocardial infarction, or stroke. It's not good for them.

Opportunities:
  • Technological advancements

The growth in the majority of migraine cases globally is one of the essential factors propelling the expansion of the migraine drugs market. The technological advancement in R&D in pharmaceutical enterprises for improving different types of migraine drugs accelerate market growth. The rising awareness among patients about the prevention and therapy of migraine and the increase in the partnerships among manufacturers further impact the market development.

Segmentation Analysis:

The global acute migraine drugs market has been segmented based on route of administration, treatment, end user, and regions.

  • The route of administration segment is divided into injection, oral, and others. The oral segment dominated the market, with a market share of around 35% in 2021. The features like quick efficacy, simplicity to take, and good absorption in the blood.
  • The treatment segment is divided into pain relieving and preventive. The preventive segment dominated the market, with a market share of around 56% in 2021. Preventative treatments decrease the frequency and disability of migraine. The significant drug classes in preventive treatments are botulin toxins, beta-blockers, and topiramate.
  • The end-user segment is divided into online pharmacies, retail pharmacies, and hospital pharmacies. The hospital pharmacies segment dominated the market, with a market share of around 37% in 2021. Increased neurological conditions, a growing number of patients, the available drugs, and the increasing prevalence of migraine is anticipated to propel market expansion.
Regional Segmentation Analysis:

The regions analyzed for the market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. North America region emerged as the largest market for the global acute migraine drugs market, with a 34.5% share of the market revenue in 2021.

North America is anticipated to lead the acute migraine drugs market stake in the evaluation time. The increasing investment by essential players established in the United States and Canada in comprehensive research and development actions to find other treatment choices is assessed to predict satisfactorily for the regional market.

North America Region Acute Migraine Drugs Market Share in 2021 - 34.5%

 

www.thebrainyinsights.com

Check the geographical analysis of this market by requesting a free sample

Competitive Analysis:

The key players are now concentrating on implementing strategies such as adopting new technology, product innovations, mergers & acquisitions, joint venture, alliances, and partnerships to improve their market position in the global acute migraine drugs industry.

In February 2022, Pfizer Inc. and Bio haven Pharmaceutical Company Ltd. declared that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) authorized Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist.

List of Key Market Players:

  • Teva Pharmaceutical
  • Pfizer Inc.
  • Novartis AG
  • Merck & Co.
  • Johnson and Johnson
  • Hoffmann-La Roche Ltd.
  • Eli Lilly and Company
  • AstraZeneca
  • Amgen

Key Target Audience

  • Hospitals
  • Online Pharmacies
  • Retail Pharmacies
  • Market Players
  • Investors
  • End-users
  • Government Authorities
  • Consulting And Research Firm
  • Venture capitalists
  • Third-party knowledge providers

Report Description:

  • Global Acute Migraine Drugs Market, Industry Analysis, Trends, Analysis and Forecast, 2022 to 2030 is a forthcoming/imminent research report which is to be published by The Brainy Insights.
  • 2021 is considered as the base year of the report. 2019 and 2020 are considered as the historic years and 2022 to 2030 are the forecast years. The global acute migraine drugs market is based on revenue (USD Billion). The report incorporates the market study based on revenue. The study covers the market share revenue/market share/volume for each of the segments, regions and countries catering to global acute migraine drugs market. The regions analyzed for the market are Europe, Asia Pacific, North America, South America, and Middle East & Africa. Furthermore, the regions are further analyzed at the country level.
  • The report encompasses with the relative data & information, which have been validated by the leading industry professionals and experts across the globe. The research report also delivers an outline of the attractiveness of acute migraine drugs based on based on route of administration, treatment, end user, and regions. which are deduced and formulated based on their growth rate (CAGR), market size, and attractiveness by analyzing the present and prospects to fathom market growth and development in future.
  • The report illustrates the detailed (both quantitative and qualitative) analysis of historical data, revenues, key developments, along with the crucial strategies adopted by key organizations catering to global acute migraine drugs market. This offers vital and in-depth insights to depict the overall market scenario.
  • The report offers the detailed study for the company profiles of key organizations operating in the global acute migraine drugs market and a comparative assessment based on their product offering, business overviews, geographic presence, business strategies, segment market share, product development & innovations, recent developments, joint venture, partnerships, mergers & acquisitions, strategic alliances, SWOT analysis, and key financial information. This helps in evaluating the overall competition present in the market scenario.
  • The report provides an elaborative assessment of the porter’s five forces analysis coupled with SWOT analysis to provide business related data and information’s. Porter’s five forces model is analyzed to understand the overall competitive scenario that is prevailing in the market. Additionally, the SWOT analysis identifies both the positive and negative attributes of the market development which influences the company growth and development to sustain and survive in the long run.
  • Along with that, the report also focuses on the market related driving factors, growth limitations (restraints), potential industry opportunities, significant trends and development which act as a key potential for the investors.
  • Potential growth prospects along with the penetration rate analysis of the product (market related i.e., global acute migraine drugs market) is covered to comprehend the adoption rate and evaluate the market size. 

Frequesntly Asked Questions

As per The Brainy Insights, the size of the acute migraine drugs market was valued at USD 4.3 billion in 2021 to USD 9.26 billion by 2030.

Global acute migraine drugs market is growing at a CAGR of 8.90% during the forecast period 2022-2030.

The global acute migraine drugs market has been segmented based on route of administration, treatment, end user, and regions. The oral segment led the market in 2021. The preventive segment led the market in 2021.

North America region emerged as the largest market for the acute migraine drugs market.

The increased demand for high-quality medicines to propel market growth.

Side-effects of drugs specified for migraine to hinder market growth.

Technological advancements will provide huge opportunities to the market.

Key players are Teva Pharmaceutical, Pfizer Inc., Novartis AG, Merck & Co., Johnson and Johnson, Hoffmann-La Roche Ltd., Eli Lilly and Company, AstraZeneca, and Amgen.

1. Introduction
    1.1. Objectives of the Study
    1.2. Market Definition
    1.3. Research Scope
    1.4. Currency
    1.5. Key Target Audience

2. Research Methodology and Assumptions

3. Executive Summary

4. Premium Insights
    4.1. Porter’s Five Forces Analysis
    4.2. Value Chain Analysis
    4.3. Top Investment Pockets
          4.3.1. Market Attractiveness Analysis by Route of Administration
          4.3.2. Market Attractiveness Analysis by Treatment
          4.3.3. Market Attractiveness Analysis by End-User
          4.3.4. Market Attractiveness Analysis by Region
    4.4. Industry Trends

5. Market Dynamics
    5.1. Market Evaluation
    5.2. Drivers
          5.2.1. The increased demand for high-quality medicines
    5.3. Restraints
          5.3.1. Side-effects of drugs specified for migraine
    5.4. Opportunities
          5.4.1. Technological advancements

6. Global Acute Migraine Drugs Market Analysis and Forecast, By Route of Administration:
    6.1. Segment Overview
    6.2. Injection
    6.3. Oral
    6.4. Others

7. Global Acute Migraine Drugs Market Analysis and Forecast, By Treatment
    7.1. Segment Overview
    7.2. Pain Relieving
    7.3. Preventive

8. Global Acute Migraine Drugs Market Analysis and Forecast, By End-User
    8.1. Segment Overview
    8.2. Online Pharmacies
    8.3. Retail Pharmacies
    8.4. Hospital Pharmacies

9. Global Acute Migraine Drugs Market Analysis and Forecast, By Regional Analysis
    9.1. Segment Overview
    9.2. North America
          9.2.1. U.S.
          9.2.2. Canada
          9.2.3. Mexico
    9.3. Europe
          9.3.1. Germany
          9.3.2. France
          9.3.3. U.K.
          9.3.4. Italy
          9.3.5. Spain
    9.4. Asia-Pacific
          9.4.1. Japan
          9.4.2. China
          9.4.3. India
    9.5. South America
          9.5.1. Brazil
    9.6. Middle East and Africa
          9.6.1. UAE
          9.6.2. South Africa

10. Global Acute Migraine Drugs Market-Competitive Landscape
    10.1. Overview
    10.2. Market Share of Key Players in the Acute Migraine Drugs Market
          10.2.1. Global Company Market Share
          10.2.2. North America Company Market Share
          10.2.3. Europe Company Market Share
          10.2.4. APAC Company Market Share
    10.3. Competitive Situations and Trends
          10.3.1. Product Launches and Developments
          10.3.2. Partnerships, Collaborations, and Agreements
          10.3.3. Mergers & Acquisitions
          10.3.4. Expansions

11. Company Profiles
    11.1. Teva Pharmaceutical
          11.1.1. Business Overview
          11.1.2. Company Snapshot
          11.1.3. Company Market Share Analysis
          11.1.4. Company Product Portfolio
          11.1.5. Recent Developments
          11.1.6. SWOT Analysis
    11.2. Pfizer Inc
          11.2.1. Business Overview
          11.2.2. Company Snapshot
          11.2.3. Company Market Share Analysis
          11.2.4. Company Product Portfolio
          11.2.5. Recent Developments
          11.2.6. SWOT Analysis
    11.3. Novartis AG
          11.3.1. Business Overview
          11.3.2. Company Snapshot
          11.3.3. Company Market Share Analysis
          11.3.4. Company Product Portfolio
          11.3.5. Recent Developments
          11.3.6. SWOT Analysis
    11.4. Merck & Co.
          11.4.1. Business Overview
          11.4.2. Company Snapshot
          11.4.3. Company Market Share Analysis
          11.4.4. Company Product Portfolio
          11.4.5. Recent Developments
          11.4.6. SWOT Analysis
    11.5. Johnson and Johnson
          11.5.1. Business Overview
          11.5.2. Company Snapshot
          11.5.3. Company Market Share Analysis
          11.5.4. Company Product Portfolio
          11.5.5. Recent Developments
          11.5.6. SWOT Analysis
    11.6. Hoffmann-La Roche Ltd
          11.6.1. Business Overview
          11.6.2. Company Snapshot
          11.6.3. Company Market Share Analysis
          11.6.4. Company Product Portfolio
          11.6.5. Recent Developments
          11.6.6. SWOT Analysis
    11.7. Eli Lilly and Company
          11.7.1. Business Overview
          11.7.2. Company Snapshot
          11.7.3. Company Market Share Analysis
          11.7.4. Company Product Portfolio
          11.7.5. Recent Developments
          11.7.6. SWOT Analysis
    11.8. AstraZeneca.
          11.8.1. Business Overview
          11.8.2. Company Snapshot
          11.8.3. Company Market Share Analysis
          11.8.4. Company Product Portfolio
          11.8.5. Recent Developments
          11.8.6. SWOT Analysis
    11.9. Amgen
          11.9.1. Business Overview
          11.9.2. Company Snapshot
          11.9.3. Company Market Share Analysis
          11.9.4. Company Product Portfolio
          11.9.5. Recent Developments
          11.9.6. SWOT Analysis

List of Table

1. Global Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion) 

2. Global Injection Acute Migraine Drugs Market, By Region, 2019-2030 (USD Billion) 

3. Global Oral Acute Migraine Drugs Market, By Region, 2019-2030 (USD Billion) 

4. Global Others Acute Migraine Drugs Market, By Region, 2019-2030 (USD Billion) 

5. Global Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion) 

6. Global Pain-Relieving Acute Migraine Drugs Market, By Region, 2019-2030 (USD Billion) 

7. Global Preventive Acute Migraine Drugs Market, By Region, 2019-2030 (USD Billion)

8. Global Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion) 

9. Global Online Pharmacies Acute Migraine Drugs Market, By Region, 2019-2030 (USD Billion) 

10. Global Retail Pharmacies Acute Migraine Drugs Market, By Region, 2019-2030 (USD Billion)

11. Global Hospital Pharmacies Acute Migraine Drugs Market, By Region, 2019-2030 (USD Billion)

12. North America Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion) 

13. North America Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion) 

14. North America Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion) 

15. U.S. Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion) 

16. U.S. Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion) 

17. U.S. Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion) 

18. Canada Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion) 

19. Canada Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion) 

20. Canada Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion) 

21. Mexico Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion) 

22. Mexico Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion) 

23. Mexico Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion) 

24. Europe Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion) 

25. Europe Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion) 

26. Europe Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion) 

27. Germany Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion) 

28. Germany Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion) 

29. Germany Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion) 

30. France Acute Migraine Drugs Market, By Route of Administration 2019-2030 (USD Billion) 

31. France Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion) 

32. France Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion) 

33. U.K. Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion) 

34. U.K. Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion) 

35. U.K. Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion) 

36. Italy Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion) 

37. Italy Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion) 

38. Italy Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion) 

39. Spain Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion) 

40. Spain Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion) 

41. Spain Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion) 

42. Asia Pacific Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion) 

43. Asia Pacific Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion) 

44. Asia Pacific Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion) 

45. Japan Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion) 

46. Japan Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion) 

47. Japan Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion) 

48. China Acute Migraine Drugs Market, By Route of Administration 2019-2030 (USD Billion) 

49. China Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion) 

50. China Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion) 

51. India Acute Migraine Drugs Market, By Route of Administration 2019-2030 (USD Billion) 

52. India Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion) 

53. India Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion) 

54. South America Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion) 

55. South America Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion) 

56. South America Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion)

57. Brazil Acute Migraine Drugs Market, By Route of Administration 2019-2030 (USD Billion) 

58. Brazil Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion) 

59. Brazil Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion) 

60. Middle East and Africa Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion) 

61. Middle East and Africa Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion) 

62. Middle East and Africa Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion) 

63. UAE Acute Migraine Drugs Market, By Route of Administration, 2019-2030 (USD Billion) 

64. UAE Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion) 

65. UAE Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion) 

66. South Africa Acute Migraine Drugs Market, By Route of Administration 2019-2030 (USD Billion) 

67. South Africa Acute Migraine Drugs Market, By Treatment, 2019-2030 (USD Billion) 

68. South Africa Acute Migraine Drugs Market, By End-User, 2019-2030 (USD Billion)  

List of Figures 

1. Global Acute Migraine Drugs Market Segmentation

2. Acute Migraine Drugs Market: Research Methodology

3. Market Size Estimation Methodology: Bottom-Up Approach

4. Market Size Estimation Methodology: Top-Down Approach

5. Data Triangulation

6. Porter’s Five Forces Analysis 

7. Value Chain Analysis 

8. Global Acute Migraine Drugs Market Attractiveness Analysis by Route of Administration

9. Global Acute Migraine Drugs Market Attractiveness Analysis by Treatment

10. Global Acute Migraine Drugs Market Attractiveness Analysis by End-User

11. Global Acute Migraine Drugs Market Attractiveness Analysis by Region

12. Global Acute Migraine Drugs Market: Dynamics

13. Global Acute Migraine Drugs Market Share by Route of Administration (2022 & 2030)

14. Global Acute Migraine Drugs Market Share by Treatment (2022 & 2030)

15. Global Acute Migraine Drugs Market Share by End-User (2022 & 2030)

16. Global Acute Migraine Drugs Market Share by Regions (2022 & 2030)

17. Global Acute Migraine Drugs Market Share by Company (2021)

This study forecasts revenue at global, regional, and country levels from 2019 to 2030. The Brainy Insights has segmented the global acute migraine drugs Market based on below mentioned segments:

Global Acute Migraine Drugs Market by Route of Administration:

  • Injection
  • Oral
  • Others

Global Acute Migraine Drugs Market by Treatment:

  • Pain Relieving
  • Preventive

Global Acute Migraine Drugs Market by End User:

  • Online Pharmacies
  • Retail Pharmacies
  • Hospital Pharmacies

Global Acute Migraine Drugs Market by Region:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
  • Asia-Pacific
    • Japan
    • China
    • India
  • South America
    • Brazil
  • Middle East and Africa  
    • UAE
    • South Africa

Methodology

Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision. 

Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.

The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.

Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:

MARKET RESEARCH PROCESS

Data Procurement:

The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.

The data procurement stage involves in data gathering and collecting through various data sources.

This stage involves in extensive research. These data sources includes:

Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:

  • The organizational databases such as D&B Hoovers, and Bloomberg that helps us to identify the competitive scenario of the key market players/organizations along with the financial information.
  • Industry/Market databases such as Statista, and Factiva provides market/industry insights and deduce certain formulations. 
  • We also have contractual agreements with various reputed data providers and third party vendors who provide information which are not limited to:
    • Import & Export Data
    • Business Trade Information
    • Usage rates of a particular product/service on certain demographics mainly focusing on the unmet prerequisites

Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.

Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.

The supply side for a domain specific market is analysed by:

  • Estimating and projecting penetration rates through analysing product attributes, availability of internal and external substitutes, followed by pricing analysis of the product.
  • Experiential assessment of year-on-year sales of the product by conducting interviews.

The demand side for the market is estimated through:

  • Evaluating the penetration level and usage rates of the product.
  • Referring to the historical data to determine the growth rate and evaluate the industry trends

In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.

Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:

  • Applying demographic along with psychographic segmentation for market evaluation
  • Determining the Micro and Macro-economic indicators for each region 
  • Examining the industry indicators prevailing in the market. 

Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:

  • Data Screening: Data screening is the process of scrutinising data/information collected from primary research for errors and amending those collected data before data integration method. The screening involves in examining raw data, identifying errors and dealing with missing data. The purpose of the data screening is to ensure data is correctly entered or not. The Brainy Insights employs objective and systematic data screening grades involving repeated cycles of quality checks, screening and suspect analysis.
  • Data Integration: Integrating multiple data streams is necessary to produce research studies that provide in-depth picture to the clients. These data streams come from multiple research studies and our in house database. After screening of the data, our analysts conduct creative integration of data sets, optimizing connections between integrated surveys and syndicated data sources. There are mainly 2 research approaches that we follow in order to integrate our data; top down approach and bottom up approach.

Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.

This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.

Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.

The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:

  • CXOs and VPs of leading companies’ specific to sector
  • Purchasing managers, technical personnel, end-users
  • Key opinion leaders such as investment bankers, and industry consultants

Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.

Some Facts About The Brainy Insights

50%

Free Customization

300+

Fortune 500 Clients

1

Free Yearly Update On Purchase Of Multi/Corporate License

900+

Companies Served Till Date